Trial Profile

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
Indications Smoldering multiple myeloma
Focus Therapeutic Use
Acronyms DETER-SMM

Most Recent Events

09 Mar 2023 Planned End Date changed from 30 Nov 2028 to 31 Dec 2029.
09 Mar 2023 Planned primary completion date changed from 30 Nov 2023 to 31 Dec 2029.
09 May 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com